[en] Cytomegalovirus (CMV) infection is a serious complication of pediatric hematopoietic stem cell transplant (HSCT). To date, antiviral therapy has been the mainstay of prophylaxis, with conflicting results regarding the benefits of CMV-specific immunoglobulins (CMV-Ig). After introducing prophylactic CMV-Ig to HSCT recipients at risk (seropositive recipient and/or donor), we conducted a single-center retrospective study comparing the incidence and severity of CMV infection with and without CMV-Ig. We identified 49 'at risk' recipients from 76 consecutive HSCTs over 3.5 years, in addition to standard antiviral prophylaxis, 10 patients received CMV-Ig and 39 did not. There was no significant difference in donor type, cell source, conditioning, or CMV status between the groups. We observed a potential trend toward reduction of incidence of CMV reactivation in patients exposed to CMV-Ig (30%) compared with those who weren't (38.4%). Besides, no symptomatic or lethal infection was observed in the CMV-Ig group, and time to recovery seemed shorter (21 [±7] vs 51.4 [±55] days) and peak titers lower (4578 [±4788] vs 24131 [±49257]) with CMV-Ig. No adverse events were noted. The statistical significance of the results was limited by the small sample size. These data raise interest in prophylactic CMV-Ig as a safe way of potentially reducing the severity and duration of CMV reactivation in HSCT.
Disciplines :
Hematology
Author, co-author :
Geurten, Claire ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie
Ghinai, Rosanna; Department of Paediatric Stem Cell Transplant, Birmingham Women and Children's NHS Foundation Trust
Munford, Haydn; Medical Liaison, Biotest UK Ltd, Birmingham, United Kingdom
Lawson, Sarah; Department of Paediatric Stem Cell Transplant, Birmingham Women and Children's NHS Foundation Trust
Language :
English
Title :
Efficacy of Cytomegalovirus Specific Immunoglobulins to Reduce CMV Reactivation in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Arcuri LJ, Schirmer M, Colares M,. Impact of anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors. Biol Blood Marrow Transplant. 2020; 26: e275-e279.
Boeckh M, Nichols WG, Papanicolaou G,. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003; 9: 543-558.
Ljungman P, Reusser P, de la Camara R,. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004; 33: 1075-1078.
Jakharia N, Howard D, Riedel DJ,. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021; 13: 123-140.
Girmenia C, Lazzarotto T, Bonifazi F,. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019; 33: e13666.
Marty FM, Ljungman P, Chemaly RF,. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017; 377: 2433-2444.
Styczyński J, Tridello G, Xhaard A,. Use of letermovir in off-label indications: infectious diseases working party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant. 2021; 56: 1171-1179.
Goldstein G, Rutenberg TF, Mendelovich SL,. The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients. Pediatr Blood Cancer. 2017; 64: e26420.
Ahn H, Tay J, Shea B,. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transfusion. 2018; 58: 2437-2452.
Raanani P, Gafter-Gvili A, Paul M,. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008; 4: CD006501.
Alsuliman T, Kitel C, Dulery R,. Cytotect® CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study. Bone Marrow Transplant. 2018; 53: 1328-1335.
Alexander BT, Hladnik LM, Augustin KM,. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010; 30: 554-561.
Ruttmann E, Geltner C, Bucher B,. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplant. 2006; 81: 1415-1420.
Malagola M, Greco R, Santarone S,. CMV Management with specific immunoglobulins: a multicentric retrospective analysis on 92 allotransplanted patients. Mediterr J Hematol Infect Dis. 2019; 11: e2019048.
